RNAi nanomedicines: Challenges and opportunities within the immune system

Nanotechnology

Volumn 21, Issue 23, 2010, Pages

  Weinstein, Shiri ^a   Peer, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNE CELLS; IMMUNE SYSTEMS; IN-VIVO; NANOCARRIERS; NANOMEDICINES; ONE STEP; PERSONALIZED MEDICINES; RECENT PROGRESS; TARGET TISSUES; THERAPEUTIC MODALITY;

NANOMATERIAL; SMALL INTERFERING RNA;

ANIMAL; CHEMISTRY; CYTOLOGY; HUMAN; IMMUNE SYSTEM; METHODOLOGY; NANOMEDICINE; REVIEW; RNA INTERFERENCE;

ANIMALS; HUMANS; IMMUNE SYSTEM; NANOMEDICINE; NANOSTRUCTURES; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 77952385213     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/21/23/232001     Document Type: Review

References (109)

1. Sledz C A and Williams B R 2005 RNA interference in biology and disease Blood 106 787-94
2. de Fougerolles A, Vornlocher H P, Maraganore J and Lieberman J 2007 Interfering with disease: a progress report on siRNA-based therapeutics Nat. Rev. Drug Discov. 6 443-53
3. Liu Z, Sall A and Yang D 2008 MicroRNA: an emerging therapeutic target and intervention tool Int. J. Mol. Sci. 9 978-99
4. Elbashir S M, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T 2001 Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells Nature 411 494-8
5. Amarzguioui M, Rossi J J and Kim D 2005 Approaches for chemically synthesized siRNA and vector-mediated RNAi FEBS Lett. 579 5974-81
6. Bartlett D W and Davis M E 2006 Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging Nucleic Acids Res. 34 322-33
7. Krek A et al 2005 Combinatorial microRNA target predictions Nat. Genet. 37 495-500
8. Singh S K, Pal Bhadra M, Girschick H J and Bhadra U 2008 MicroRNAs-micro in size but macro in function FEBS J. 275 4929-44
9. Esau C C and Monia B P 2007 Therapeutic potential for microRNAs Adv. Drug Deliv. Rev. 59 101-14
10. Love T M, Moffett H F and Novina C D 2008 Not miR-ly small RNAs: big potential for microRNAs in therapy J. All. Clin. Immunol. 121 309-19
11. Kedmi R and Peer D 2009 RNAi nanoparticles in the service of personalized medicine Nanomedicine 4 853-5
12. Robbins M, Judge A, Ambegia E, Choi C, Yaworski E, Palmer L, McClintock K and MacLachlan I 2008 Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation Human Gene. Therapy 19 991-9
13. Kleinman M E et al 2008 Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 Nature 452 591-7
14. Ma M et al 2009 Decreased cofilin1 expression is important for compaction during early mouse embryo development Biochim. Biophys. Acta 1793 1804-10
15. Bose S, Leclerc G M, Vasquez-Martinez R and Boockfor F R 2010 Administration of connexin43 siRNA abolishes secretory pulse synchronization in GnRH clonal cell populations Mol. Cell Endocrinol. 314 75-83
16. Wiese M, Castiglione K, Hensel M, Schleicher U, Bogdan C and Jantsch J 2009 Small interfering RNA (siRNA) delivery into murine bone marrow-derived macrophages cells by electroporation J. Immunol. Methods 353 102-10
17. Honjo K et al 2009 MDR1a/1b gene silencing enhances drug sensitivity in rat fibroblast-like synoviocytes J. Gene Med. 12 219-27
18. Grandjean V, Gounon P, Wagner N, Martin L, Wagner K D, Bernex F, Cuzin F and Rassoulzadegan M 2009 The miR-124-Sox9 paramutation: RNA-mediated epigenetic control of embryonic and adult growth Development 136 3647-55
19. Vidic S, Markelc B, Sersa G, Coer A, Kamensek U, Tevz G, Kranjc S and Cemazar M 2010 MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo Cancer Gene Therapy at press
20. Donze O and Picard D 2002 RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase Nucleic Acids Res. 30 e46
21. Zhang M, Bai C X, Zhang X, Chen J, Mao L and Gao L 2004 Downregulation enhanced green fluorescence protein gene expression by RNA interference in mammalian cells RNA Biol. 1 74-7
22. Gosain A K, Machol J A t, Gliniak C and Halligan N L 2009 TGF-beta1 RNA interference in mouse primary dura cell culture: downstream effects on TGF receptors, FGF-2, and FGF-R1 mRNA levels Plast. Reconstr. Surg. 124 1466-73
23. Cheng S Q, Wang W L, Yan W, Li Q L, Wang L and Wang W Y 2005 Knockdown of survivin gene expression by RNAi induces apoptosis in human hepatocellular carcinoma cell line SMMC-7721 World J. Gastroenterol. 11 756-9
24. Baker B E, Kestler D P and Ichiki A T 2006 Effects of siRNAs in combination with Gleevec on K-562 cell proliferation and Bcr-Abl expression J. Biomed. Sci. 13 499-507
25. Karimi M H, Ebadi P, Pourfathollah A A, Soheili Z S, Samiee S, Ataee Z, Tabei S Z and Moazzeni S M 2009 Immune modulation through RNA interference-mediated silencing of CD40 in dendritic cells Cell Immunol. 259 74-81
26. Zhou J Y, Ma W L, Fei J, Ding D P, Shi R, Jiang L and Zheng W L 2006 Effects of microRNA miR-181a on gene expression profiles of K562 cells Nan Fang Yi Ke Da Xue Xue Bao 26 606-9
27. Migliore C, Petrelli A, Ghiso E, Corso S, Capparuccia L, Eramo A, Comoglio P M and Giordano S 2008 MicroRNAs impair MET-mediated invasive growth Cancer Res. 68 10128-36
28. Crombez L, Charnet A, Morris M C, Aldrian-Herrada G, Heitz F and Divita G 2007 A non-covalent peptide-based strategy for siRNA delivery Biochem. Soc. Trans. 35 44-6
29. Muratovska A and Eccles M R 2004 Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells FEBS Lett. 558 63-8
30. Minakuchi Y et al 2004 Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo Nucleic Acids Res. 32 e109
31. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S and Muramatsu T 2004 A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics Cancer Res. 64 3365-70
32. Puebla I, Esseghir S, Mortlock A, Brown A, Crisanti A and Low W 2003 A recombinant H1 histone-based system for efficient delivery of nucleic acids J. Biotechnol. 105 215-26
33. Bitko V, Musiyenko A, Shulyayeva O and Barik S 2005 Inhibition of respiratory viruses by nasally administered siRNA Nat. Med. 11 50-5
34. Palliser D, Chowdhury D, Wang Q Y, Lee S J, Bronson R T, Knipe D M and Lieberman J 2006 An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection Nature 439 89-94
35. Kim B et al 2004 Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis Am. J. Pathol. 165 2177-85
36. Trang P et al 2009 Regression of murine lung tumors by the let-7 microRNA Oncogene 29 1580-7
37. Nagata Y, Nakasa T, Mochizuki Y, Ishikawa M, Miyaki S, Shibuya H, Yamasaki K, Adachi N, Asahara H and Ochi M 2009 Induction of apoptosis in the synovium of mice with autoantibody-mediated arthritis by the intraarticular injection of double-stranded MicroRNA-15a Arthritis Rheum 60 2677-83
38. Novobrantseva T I, Akinc A, Borodovsky A and de Fougerolles A 2008 Delivering silence: advancements in developing siRNA therapeutics Curr. Opin. Drug Discov. Devel. 11 217-24
39. Peer D and Shimaoka M 2009 Systemic siRNA delivery to leukocyte-implicated diseases Cell Cycle 8 853-9
40. Zender L and Kubicka S 2007 Suppression of apoptosis in the liver by systemic and local delivery of small-interfering RNAs Methods Mol. Biol. 361 217-26
41. De Souza A T et al 2006 Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown mice Nucleic Acids Res. 34 4486-94
42. Saito Y et al 2007 Osteopontin small interfering RNA protects mice from fulminant hepatitis Human Gene. Therapy 18 1205-14
43. Lewis D L and Wolff J A 2007 Systemic siRNA delivery via hydrodynamic intravascular injection Adv. Drug Deliv. Rev. 59 115-23
44. Molitoris B A et al 2009 siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury J. Am. Soc. Nephrol. 20 1754-64
45. Braasch D A, Jensen S, Liu Y, Kaur K, Arar K, White M A and Corey D R 2003 RNA interference in mammalian cells by chemically-modified RNA Biochemistry 42 7967-75
46. Mook O R, Baas F, de Wissel M B and Fluiter K 2007 Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo Mol. Cancer Ther. 6 833-43
47. Glud S Z, Bramsen J B, Dagnaes-Hansen F, Wengel J, Howard K A, Nyengaard J R and Kjems J 2009 Naked siLNA-mediated gene silencing of lung bronchoepithelium EGFP expression after intravenous administration Oligonucleotides 19 163-8
48. Ferrari M 2005 Cancer nanotechnology: opportunities and challenges Nat. Rev. Cancer 5 161-71
49. LaVan D A, McGuire T and Langer R 2003 Small-scale systems for in vivo drug delivery Nat. Biotechnol. 21 1184-91
50. Whitesides G M 2003 The 'right' size in nanobiotechnology Nat. Biotechnol. 21 1161-5
51. Peer D, Karp J M, Hong S, Farokhzad O C, Margalit R and Langer R 2007 Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2 751-60
52. Iyer A K, Khaled G, Fang J and Maeda H 2006 Exploiting the enhanced permeability and retention effect for tumor targeting Drug Discov. Today 11 812-8
53. Couvreur P and Vauthier C 2006 Nanotechnology: intelligent design to treat complex disease Pharm. Res. 23 1417-50
54. Yuan F, Dellian M, Fukumura D, Leunig M, Berk D A, Torchilin V P and Jain R K 1995 Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size Cancer Res. 55 3752-6
55. Torchilin V P 2005 Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discov. 4 145-60
56. Hobbs S K, Monsky W L, Yuan F, Roberts W G, Griffith L, Torchilin V P and Jain R K 1998 Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment Proc. Natl Acad. Sci. USA 95 4607-12
57. Maeda H, Sawa T and Konno T 2001 Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS J. Control Release 74 47-61
58. Matsumura Y and Maeda H 1986 A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 6387-92
59. Zimmermann T S et al 2006 RNAi-mediated gene silencing in non-human primates Nature 441 111-4
60. Morrissey D V et al 2005 Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs Nat. Biotechnol. 23 1002-7
61. Lv H, Zhang S, Wang B, Cui S and Yan J 2006 Toxicity of cationic lipids and cationic polymers in gene delivery J. Control Release 114 100-9
62. Ma Z, Li J, He F, Wilson A, Pitt B and Li S 2005 Cationic lipids enhance siRNA-mediated interferon response in mice Biochem. Biophys. Res. Commun. 330 755-9
63. Geisbert T W et al 2006 Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference J. Infect Dis. 193 1650-7
64. Semple S C et al 2010 Rational design of cationic lipids for siRNA delivery Nat. Biotechnol. 28 172-6
65. Villares G J et al 2008 Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA Cancer Res. 68 9078-86
66. Landen C N Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers M T, Lopez-Berestein G and Sood A K 2005 Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery Cancer Res. 65 6910-8
67. Akinc A et al 2008 A combinatorial library of lipid-like materials for delivery of RNAi therapeutics Nat. Biotechnol. 26 561-9
68. Love K T et al 2010 Lipid-like materials for low-dose, in vivo gene silencing Proc. Natl Acad. Sci. USA 107 1864-9
69. Leng Q, Goldgeier L, Zhu J, Cambell P, Ambulos N and Mixson A J 2007 Histidine-lysine peptides as carriers of nucleic acids Drug News Perspect. 20 77-86
70. Leng Q, Scaria P, Lu P, Woodle M C and Mixson A J 2008 Systemic delivery of HK Raf-1 siRNA polyplexes inhibits MDA-MB-435 xenografts Cancer Gene Therapy 15 485-95
71. Yan Z, Zou H, Tian F, Grandis J R, Mixson A J, Lu P Y and Li L Y 2008 Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth Mol. Cancer Ther. 7 1355-64
72. Ochiya T, Takahama Y, Nagahara S, Sumita Y, Hisada A, Itoh H, Nagai Y and Terada M 1999 New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet Nat. Med. 5 707-10
73. Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, Nagahara S, Kato K and Ochiya T 2008 RPN2 gene confers docetaxel resistance in breast cancer Nat. Med. 14 939-48
74. Fujii T et al 2006 Intratumor injection of small interfering RNA-targeting human papillomavirus 18 E6 and E7 successfully inhibits the growth of cervical cancer Int. J. Oncol. 29 541-8
75. Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu K and Takei Y 2009 Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer Int. J. Cancer 125 2978-90
76. Takeshita F et al 2010 Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes Mol. Ther. 18 181-7
77. Wolfrum C et al 2007 Mechanisms and optimization of in vivo delivery of lipophilic siRNAs Nat. Biotechnol. 25 1149-57
78. Nishina K, Unno T, Uno Y, Kubodera T, Kanouchi T, Mizusawa H and Yokota T 2008 Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol Mol. Ther. 16 734-40
79. Lorenz C, Hadwiger P, John M, Vornlocher H P and Unverzagt C 2004 Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells Bioorg. Med. Chem. Lett. 14 4975-7
80. Krutzfeldt J, Rajewsky N, Braich R, Rajeev K G, Tuschl T, Manoharan M and Stoffel M 2005 Silencing of microRNAs in vivo with 'antagomirs' Nature 438 685-9
81. Rozema D B et al 2007 Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes Proc. Natl Acad. Sci. USA 104 12982-7
82. Schiffelers R M, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu P Y, Scaria P V and Woodle M C 2004 Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle Nucleic Acids Res. 32 e149
83. Hu-Lieskovan S, Heidel J D, Bartlett D W, Davis M E and Triche T J 2005 Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma Cancer Res. 65 8984-92
84. Davis M E 2009 The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic Mol. Pharm. 6 659-68
85. Davis M E, Zuckerman J E, Choi C H, Seligson D, Tolcher A, Alabi C A, Yen Y, Heidel J D and Ribas A 2010 Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Nature 464 1067-70
86. Andrabi S M 2007 Mammalian sperm chromatin structure and assessment of DNA fragmentation J. Assist. Reprod. Genet. 24 561-9
87. Song E et al 2005 Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors Nat. Biotechnol. 23 709-17
88. Kumar P, Wu H, McBride J L, Jung K E, Kim M H, Davidson B L, Lee S K, Shankar P and Manjunath N 2007 Transvascular delivery of small interfering RNA to the central nervous system Nature 448 39-43
89. McNamara J O 2nd, Andrechek E R, Wang Y, Viles K D, Rempel R E, Gilboa E, Sullenger B A and Giangrande P H 2006 Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras Nat. Biotechnol. 24 1005-15
90. Dassie J P, Liu X Y, Thomas G S, Whitaker R M, Thiel K W, Stockdale K R, Meyerholz D K, McCaffrey A P, McNamara J O 2nd and Giangrande P H 2009 Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors Nat. Biotechnol. 27 839-49
91. Sato Y et al 2008 Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone Nat. Biotechnol. 26 431-42
92. Pirollo K F, Rait A, Zhou Q, Hwang S H, Dagata J A, Zon G, Hogrefe R I, Palchik G and Chang E H 2007 Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system Cancer Res. 67 2938-43
93. Li S D, Chen Y C, Hackett M J and Huang L 2008 Tumor-targeted delivery of siRNA by self-assembled nanoparticles Mol. Ther. 16 163-9
94. Kortylewski M et al 2009 In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses Nat. Biotechnol. 27 925-32
95. Kumar P et al 2008 T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice Cell 134 577-86
96. Subramanya S et al 2009 Targeted delivery of siRNA to human dendritic cells to suppress Dengue viral infection and associated proinflammatory cytokine production J. Virol. 84 2490-501
97. Zheng X et al 2009 A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation Blood 113 2646-54
98. Peer D, Zhu P, Carman C V, Lieberman J and Shimaoka M 2007 Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1 Proc. Natl Acad. Sci. USA 104 4095-100
99. Shimaoka M, Takagi J and Springer T A 2002 Conformational regulation of integrin structure and function Annu. Rev. Biophys. Biomol. Struct. 31 485-516
100. Cauli A, Yanni G, Pitzalis C, Challacombe S and Panayi G S 1995 Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sjogren's syndrome and chronic sialoadenitis Ann. Rheum. Dis. 54 209-15
101. Tanaka Y et al 1998 Constitutive chemokine production results in activation of leukocyte function-associated antigen-1 on adult T-cell leukemia cells Blood 91 3909-19
102. Peer D, Florentin A and Margalit R 2003 Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes Biochim. Biophys. Acta 1612 76-82
103. Peer D and Margalit R 2004 Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models Int. J. Cancer 108 780-9
104. Peer D and Margalit R 2004 Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models Neoplasia 6 343-53
105. Peer D, Park E J, Morishita Y, Carman C V and Shimaoka M 2008 Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target Science 319 627-30
106. Dearling J L, Park E J, Dunning P, Baker A, Fahey F, Treves S T, Soriano S G, Shimaoka M, Packard A B and Peer D 2010 Detection of intestinal inflammation by MicroPET imaging using a (64)Cu-labeled anti-beta(7) integrin antibody Inflamm. Bowel Dis. at press
107. Kim S S et al 2009 RNAi-mediated CCR5 Silencing by LFA-1-targeted Nanoparticles Prevents HIV Infection in BLT Mice Mol. Ther. 18 370-6
108. Tong A W and Nemunaitis J 2008 Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Therapy 15 341-55
109. O'Connell R M, Rao D S, Chaudhuri A A and Baltimore D 2010 Physiological and pathological roles for microRNAs in the immune system Nat. Rev. Immunol. 10 111-22